Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer

Alberta Health services

Status and phase: Completed; Phase 2; Phase 1

Conditions: Prostate Cancer

Treatments: Procedure: radiotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT00126165

17885

Details and patient eligibility

About

This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.

Full description

This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determining the morbidity and cancer control provided by a 4-week course of treatment will greatly influence future radiotherapy services for patients with localized prostate cancer.

Enrollment: 72 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage T1 and T2 prostate cancer
• Prostate specific antigen (PSA)>=20 and Gleason score<=6
• PSA<=15 and Gleason score 7
• Signed informed consent

Exclusion criteria

• No hip prosthesis, pins or screws
• No previous pelvic radiotherapy
• No inflammatory bowel disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)